Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone + granisetron patch versus dexamethasone + aprepitant + 5-HT3 antagonist for prevention of delayed chemotherapy-induced nausea and vomiting
ChiCTR2300068304Phase 4Not yet recruiting
- Sponsor
- The Seventh Affiliated Hospital, Sun Yat-sen University
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of granisetron, dexamethasone and aprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by The Seventh Affiliated Hospital, Sun Yat-sen University. Primary endpoint: Complete response rate in the delayed phase. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
granisetrondexamethasoneaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2300068304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068304.